1st Edition

Fibrinolysis in Disease - The Malignant Process, Interventions in Thrombogenic Mechanisms, and Novel Treatment Modalities, Volume 2

By Pia Glas-Greenwalt Copyright 1995

    Fibrinolysis in Disease reviews the state of the art of basic and clinical aspects of the fibrinolytic enzyme system. The text, authored by outstanding and internationally known investigators, is presented in two books.
    The Malignant Process, Interventions in Thrombogenic Mechanisms, and Novel Treatment Modalities discusses the molecular biology of the system's key components and their fundamental roles in a variety of thrombotic and metabolic disorders. Molecular and Hemovascular Aspects of Fybrinolysis presents the latest findings and concepts of the association between plasminogen activator (u-PA) overexpression and abnormal growth regulation in a variety of solid tumors and in leukemia. One chapter deals with various successful interventions in thrombogenic mechanisms, ranging from exercise and diet to anticoagulants and direct and indirect thrombolytic agents. It concludes with a projection of exciting, novel treatment modalities in thrombotic and malignant diseases.

    of The Malignant Process:
    The Role of the Plasminogen Activation System in Neoplasia
    uPA Production, Receptor Display, and Differentiation, D. Boyd and M. Brattain
    Interactions between Epidermal Growth Factor and Its Receptor in the Regulation of Urokinase Plasminogen Activator in Normal and Malignant Keratinocytes, M.J. Niedbala and A.C. Sartorelli
    Tissue-Type and Urokinase-Type Plasminogen Activators as Prognostic Markers in Breast Cancer, M.J. Duffy, D. Reilly, P. O'Grady, N. Nolan, N. O'Higgins, J.J. Fennelly, and P.A. Andreasen
    Both uPA and PAI-1 Are Independent Prognosticators of Relapse and Death in Breast Cancer, F. Jänicke, M. Schmitt, and H. Graeff
    PAI-1 and PAI-2 Levels as Predictors in Staging Malignancy in Breast Cancer, K. Sumiyoshi, T. Urano, Y. Takada, and A. Takada
    Plasminogen Activation in Ovarian Cancer, B. Casslén and B. Astedt
    Increased Urokinase-Plasminogen Activator (u-PA) Expression Correlates with the Aggressive Phenotype in Human Prostate Cancer Cells, J.M. Kozlowski, H.N. Keer, F.D. Gaylis, and C. Lee
    Epidermal Growth Factor Receptor and Plasminogen Activators in Bladder Cancer, D.J. Thomas and D.E. Neal
    Role of u-PA in Determining the Biological Behavior of Gastric Cancer, S. Takai, M. Yamamura, S. Uetsuji, and M. Yamamoto
    u-PA Levels in Plasma, Urine, and Tissues of Patients with Cancer of the Digestive Tract, N. Nishino, S. Baba, and A. Takada
    u-PA:t-PA Ratio as Discriminator in Gastrointestinal Cancer, H.W. Verspaget
    Plasminogen Activators in Osteoblastic Cells, L.C. Carpio and R. Dziak
    u-PA as an Autocrine Mitogen in Human Melanoma Cells, B.R. Binder and M. Ruthner
    PAI-1 and PAI-2 in Leukemic Patients, B. Bennett and A. Croll
    Interventions
    Exercise
    Effects of Physical Training and Smoking Cessation on PAI Levels, J.-C. Gris and J.-F. Schved
    Fibrinolytic Response to Strenuous Physical Exercise, J.-B. Hansen
    Diet
    Hyperlipidemia and Reduced Fibrinolysis-Diet or Drugs? P. Andersen
    Effect of Fish Oil on Some Parameters of Fibrinolysis, O. Haglund, T.G.P. Saldeen, and J.L. Mehta
    Diet and Fibrinolysis, with Special Reference to the Effects of Fiber Intake, T.K. Nilsson, K. Boman, J.-X. Zhang, and G. Hallmans
    Direct Thrombolytic Agents
    Conjunctive Thrombolytic and Antithrombotic Therapy for Acute Myocardial Infarction, H.J. Rapold
    Platelet Activation During Thrombolytic Therapy in Unstable Angina, M. Reilly and D.J. Fitzgerald
    Paradoxic Prothrombotic Effects During Pharmacologic Thrombolysis, G.A. Ewald and P.R. Eisenberg
    Plasma Fibrinopeptide A and B Levels May Not Be Specific Markers of Thrombin Activity During Pharmacologic Thrombolysis, J.I. Weitz
    Efficient Coronary Thrombolysis Is Dependent on Concentrations of Free t-PA, C.L. Lucore
    Thrombolytic Therapy in Patients with Acute Massive Pulmonary Embolism, M. Verstraete
    Thrombolysis in Cerebrovascular Ischemia, G.J. del Zoppo
    Indirect Thrombolytic Agents
    Use of Ancrod in Patients with Heparin-Induced Thrombocytopenia and During Cardiopulmonary Bypass Surgery, K. Aogaichi
    Therapy with Ancrod in Acute Ischemic Stroke, D.E. Levy
    Fibrinolytic and Clinical Effects of Ancrod in Systemic Lupus Erythematosus and Acute Ischemic Stroke, P. Glas-Greenwalt
    Fibrinolytic Response to dDAVP and Its Potential Clinical Relevance, E. Törnebohm-Roche
    Heparin and Others
    Interaction of Heparin with Plasminogen Activators and Plasminogen In Vitro, D.C. Rijken, G.A.W. de Munk, and A.F.H. Jie
    Profibrinolytic Effects of Modified Heparins, R. Porta and R. Pescador
    Disease and Drug Modulation of Fibrinolysis, J. Fareed, P. Bacher, J.M. Walenga, D.A. Hoppensteadt, and E.W. Bermes
    Future
    Genetically Engineered New Thrombolytic Agents, H.R. Lijnen and D. Collen
    Antibody Targeting of Plasminogen Activators, M.S. Runge, K.W. Harris, and C. Bode
    The Potential Use of Anti-PAI-1 Antibodies as Adjuvants in Thrombolytic Therapy, M. Levi and B.J. Biemond
    Vampire Bat Salivary Plasminogen Activator, S.J. Gardell
    Stimulation of Indigenous Fibrinolysis: A Novel Approach of Prevention from Thrombosis, G. Dooijewaard and C. Kluft
    The Potentials of Retinoids as Stimulators of Endogenous Tissue-Type Plasminogen Activator, T. Kooistra
    Growth Factor Mechanisms and Cancer Therapy, K.R. Meehan and L.R. Zacharski

    Biography

    Pia Glas-Greenwalt, M.D., is Director of the Fibrinolysis/Special Coagulation Laboratory at the Good Samaritan Hospital and affiliated with the Department of Internal Medicine at the University of Cincinnati Medical Center, Cincinnati, Ohio. She received her M.D. degree from the Eberhard Karl University School of Medicine in Tübingen, Germany (1961) and training in biochemistry at the James F. Mitchell Foundation, Institute for Medical Research, in Washington, D.C., where she was senior investigator from 1970 to 1975. Prior to joining the College of Medicine in Cincinnati, she was head of coagulation at the National Naval Medical Center, Bethesda, Maryland (1975 to 1979).